Modulation of angiogenesis by inflammatory markers and the role of matrix metalloproteinases in an endothelial cell/fibroblast co-culture system.

BARRON, G.A., BORDET, E., GOUA, M. and BERMANO. G.

2014
INTRODUCTION

Inflammatory markers such as tumour necrosis factor-α (TNFα) [1], interleukin-6 (IL-6) [2], along with leptin [2] and hepatocyte growth factor (HGF) [3] have been shown to be elevated in plasma of obese individuals [4] and considered a major risk factor for the development of long term chronic conditions (e.g., cardiovascular disease, type 2 diabetes, stroke and cancer) [5, 6] and vascular complications [7]. As some of these inflammatory markers have been implicated in the increased development of angiogenesis [8-11], it is very important to identify and characterise the role that such inflammatory markers have on modulating angiogenesis.

Angiogenesis, or the growth of new blood vessels, is an important multi-step process, which occurs both in the maintenance of health and in certain disease states [12]. It plays a key role in normal vascular tissue development and repair (e.g., natural wound healing), but, when disease occurs, it can be deregulated and end in an abnormal increase of vessel density (e.g., tumourgenesis, diabetic retinopathy and atherosclerotic plaques) [13]. Additionally, angiogenesis plays a crucial role in the modulation of adipogenesis [14].

Angiogenesis involves an extensive interplay between a variety of growth factors, cytokines, enzymes and cells, together with extracellular matrix (ECM) components [13, 15, 16]. Vascular endothelial growth factor (VEGF) is a major angiogenic growth factor that stimulates proliferation and migration of endothelial cells (EC) [17] and is secreted by almost all tissue cell types and, interestingly, elevated levels of inflammatory markers typically associated with obese status, affect tubule formation differently in a heterogeneous cell environment similar to that observed in vivo.

MMP enzymes are a family of structurally related proteinases which are readily able to degrade all components of the ECM [20, 21]. The regulation of MMP activity is known to play a key role in EC migration during angiogenesis [22]. There is little or no basal production of MMP enzymes in most cell types. However, MMP expression and activity are inducible: with regulators known to include growth factors, cytokines and cell-matrix interactions, and their role in cancer has been implicated in tumour invasion and metastasis [21]. More specifically, MMP-2 (Gelatinase A, 72 kDa) and MMP-9 (Gelatinase B, 92 kDa), which degrade denatured collagens and basement membrane components, have been associated with this process [21]. MMP-2 is typically produced in most human tissue cell types and, interestingly, elevated levels of MMP-2 are associated with invasive behaviour [23].
Several *in vitro* and *in vivo* methods have been established over the years to study the factors that influence angiogenesis. These include monoculture assays (such as motility assays, matrigel formation or proliferation assays) or organ and tissue-specific assays (such as cornea assay or the chick chorioallantoic membrane (CAM) assay) [24]. However, the co-culture assay system established by Bishop and colleagues [15], in which primary human EC and primary normal human dermal fibroblasts are grown together, overcomes the limitations of the former assays and, in particular, can be used to observe the generation and growth of endothelial tubules, as well as inhibition, within a heterogeneous cellular environment [24]. In this study, the co-culture system established by Bishop et al. [15] has been further developed to create a more versatile system which allows the additional study of the correlation between specific inflammatory markers and vessel formation and progression.

The present study aimed to use this more versatile *in vitro* co-culture system to determine the role of TNFα and IL-6 – two highly elevated pro-inflammatory cytokines, typically associated to the obese status – in modulating (i) tubule formation and (ii) cell-cell interactions via MMP enzyme activity and secretion of VEGF, E-selectin and PGE₂.

Using the versatile co-culture assay model, treatment-specific and time-dependent differences in tubule formation were observed; IL-6 significantly increased tubule formation, whilst TNFα significantly inhibited it. Moreover, treatment specific differences in levels of MMP enzyme activities - which influence tubule formation - were observed. These results add further knowledge to the understanding of the role of inflammatory markers, commonly associated to the obese status, in modulating angiogenesis.

**MATERIALS AND METHODS**

**Materials**

All chemicals and cell culture reagents were purchased from Sigma-Aldrich Ltd (UK) unless otherwise stated.

**Cell Culture**

Primary human umbilical vein endothelial cells (HUVEC) and primary normal human dermal fibroblasts (NHDF) were obtained from Clonetics (Lonza, UK). HUVEC were maintained in endothelial basal medium (EBM-2; Clonetics, Lonza, UK) supplemented with EGM-2 SingleQuots (Clonetics, Lonza, UK) (i.e., EGM-2 medium) whilst NHDF were maintained in fibroblast basal medium (FBM; Clonetics, Lonza, UK) supplemented with FGM-2 Single Quots (Clonetics, Lonza, UK) (i.e., FGM-2 medium).

The EC/fibroblast co-culture system was set up using HUVEC (between passages 1-8) and NHDF (between passages 1-12) following the protocol established by Bishop and colleagues [15]. HUVEC and NHDF were mixed and seeded in 24 well plates (Thermo Fisher Scientific Nunc, UK) in EGM-2 medium. Co-cultured cells were incubated for up to 14 days at 37°C in a 5% CO₂ in air humidified incubator.

The co-culture system was manipulated and tested by removing VEGF from the EGM-2 medium (EGM-2Ø: EGM-2 medium minus the SingleQuot of VEGF) and by adding exogenous VEGF (50 ng/mL) and/or anti-VEGF (50 ng/mL).

**Cell Viability by Enzymatic Conversion**

HUVEC and NHDF (1x10⁵ cells/mL) were incubated with different concentrations of TNFα or IL-6 (100 µL/well; 96 hours) in EGM-2 and FGM-2 medium, respectively. Cell viability was evaluated by MTT ((3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay [25]. Absorbance was read at 560 nm in a plate reader (Bio-Tek, UK).

**Co-culture Treatment**

The co-culture system was incubated with EGM-2 medium to initiate tubule formation and, 2 and/or 7 days after co-culture establishment, medium was changed to EGM-2Ø (i.e., EGM-2 medium minus VEGF SingleQuot), EGM-2Ø supplemented with 10 ng/mL TNFα (EGM-2Ø+TNFα) or EGM-2Ø supplemented with 10 ng/mL IL-6 (EGM-2Ø+IL-6). The medium was collected 4 days and replaced with respective treatments. Collected medium was stored at -20°C until use.

The expression of secreted VEGF (DuoSetELISA, R&D Systems, Cat# DY293B), human E-selectin/CD62E (DuoSet ELISA, R&D Systems, Cat# DY724) and human prosta- glandin E₂ (PGE₂: Parameter ELISA, R&D Systems, Cat# KGE0004B) in the collected media were measured according to manufacturer’ instructions. These assays have a sensitivity of approximately 30 pg/mL and quantify both the natural and recombinant forms of each protein.

**Immunostaining**

After 14 days, co-cultures were fixed at room temperature with ice-cold 70% (v/v) ethanol and stained with myeloma cell adhesion molecule (MCAM (CD146); specific to HUVEC) or collagen type IV to assess the extent of tubule formation. MCAM allowed the visualisation of tubule formation and growth and was detected with monoclonal mouse anti-human MCAM antibody (R&D Systems, USA) with the secondary goat anti-mouse IgG (whole antibody) conjugated with alkaline phosphatase. Sigma FAST 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) was the substrate with the reaction yielding a dark purple end product. The co-cultures were dried overnight at room temperature.
and analysed. Collagen type IV was used to visualise the presence of lumen. A monoclonal mouse anti-human collagen type IV antibody was used with the same secondary and substrate as before.

Co-cultures were viewed using an Olympus 1XS1 microscope with Olympus TL4 light box. The image software used was Infinity Capture Application Version 5.0.0 (Lumenera Corporation, Canada) with camera model Infinity 2-2c. Three images per well were captured and saved as BMP images of 1616 x 1216 pixels. Illumination was set to give a best contrast between stained tubules and unstained fibroblasts. Tubule formation was defined by total tubule length and quantification was achieved by AngioSys® software Version 1.0 (TCS Cell Works, UK).

Gel Zymography

For the analysis of MMP-2 and MMP-9 enzyme activity, the medium was collected from 3 separate experiments and quantification of the total protein secreted carried out by the Bradford protein assay, according to manufacturer’s instructions. MMP enzyme activity was assessed in relation to tubule formation at the end of co-culture incubation by gel zymography adapted from Connelly and colleagues [22]. Briefly, equal volumes of samples were loaded onto a 10% SDS-polyacrylamide gel containing 0.1% (v/v) porcine gelatin. After electrophoresis, to remove the SDS, the gels were washed twice for 15 minutes each in 2.5% (v/v) Triton X-100 and then incubated overnight at 37°C in substrate buffer (50 mM Tris-HCl, pH 7.6 and 10 mM CaCl2) in the absence and presence of 10 mM EDTA. Gels were stained for 40 minutes with two changes of 0.5% Coomassie Blue R-250 (ICN Biomedical, USA), destained twice for 20 minutes in 50% (v/v) methanol, 10% (v/v) acetic acid and dried (Dry Ease Mini Gel drying system, Invitrogen, UK). MMP enzymes were visualised with areas of gelatinolytic activity which appear to be clear against the dark background of the stained gel. MMP enzymes were analysed using Image J 1.43u software (NIH, USA) and a Kaleidoscope Precision Plus Protein Standard (Bio-Rad, UK) was used to determine the molecular weight of each MMP band.

Statistical Analysis

Unless otherwise stated, all data are expressed as mean ± SEM of three independent experiments from different cell passage numbers. Statistical differences were determined by unpaired t-test (Graphpad Prism) or by one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison t-test (Graphpad Prism). P<0.05 was considered to be statistically significant.

RESULTS

Effect of TNFα or IL-6 on Cell Viability

Cell viability in HUVEC and NHDF was quantified by MTT assay where mitochondrial activity is assumed to reflect the rate of cell metabolism and, thus, the rate of enzymatic conversion is directly representative of cell viability. The cells were incubated with different concentrations (0.01-200 ng/mL) of TNFα or IL-6 for 96 hours (Fig. 1). The percentage cell viability was normalised to the corresponding untreated control (i.e., PBS for TNFα or H2O for IL-6).

No change to cell viability, compared to the control, was observed between 0.01-10 ng/mL TNFα in HUVEC, but cell viability was significantly decreased with 100 and 200 ng/mL TNFα; by 25 and 18%, respectively (Fig. 1A). In creased cell viability, compared to the control, was observed between 0.01-1 ng/mL TNFα in NHDF with a significant increase of 119, 112 and 107% with 10, 100 and 200 ng/mL TNFα, respectively (Fig. 1B). No change to cell viability, compared to the control, was observed with 0.01-200 ng/mL IL-6 in either HUVEC (Fig. 1A) or NHDF (Fig. 1B). Thus, 10 ng/mL was chosen for both cytokines to be used for tubule formation experiments.

Versatility of the Co-Culture System Used

MCAM and collagen type IV staining were used throughout this study to assess tubule formation and growth (Fig. 2A), together with quantification of total tubule length using AngioSys software analysis. The formation of tubules mimicking the process of angiogenesis was observed, over 14 days, and structures resembling a microvasculature bed developed (Fig. 2B). The co-culture system was manipulated to test its dependence from the content of VEGF in the medium by incubating the co-culture in EGM-2 and either adding exogenous VEGF (50 ng/mL) and/or anti-VEGF (50 ng/mL) (Fig. 2C). The extent of tubule formation observed in the different culture conditions (Fig. 2) highlights the versatility and usability of this system. Tubule formation obtained from cells co-cultured in EGM-2 medium was chosen as a positive control throughout this study.
Fig. (1). Effect of TNFα or IL-6 on (A) HUVEC and (B) NHDF viability. Cell viability was determined using MTT assay after 96 hours. Data are mean ± SEM of 3 independent experiments; each experiment consisted of 4 replicates per concentration; *P<0.05, **P<0.01, ***P<0.001. Note changes to the % cell viability scale (i.e., y axis).

Effect of TNFα or IL-6 on Tubule Formation

The effect of TNFα or IL-6 on tubule formation was tested with EGM-2Ω medium in order to examine tubule formation in the absence of VEGF. Co-cultures were initially incubated in EGM-2 medium (Day 0) and, after establishment, EGM-2Ω, EGM-2Ω+TNFα or EGM-2Ω+IL-6 were added after 2 and/or 7 days (Fig. 3). These conditions were used to assess the ability of these cytokines to respectively (i) promote/prevent tubule formation, or (ii) increase/reduce tubule formation once the process has already started.

Tubules were clearly formed and visualised after 14 days (Fig. 3A) and similar results were obtained in each experiment. The extent of tubule formation was quantified by measuring total tubule length and percentage change was normalised to the control (i.e., EGM-2Ω) (Fig. 3B). Tubule formation was significantly increased (43% increase) in EGM-2 medium incubated co-cultures compared to control co-cultures. TNFα significantly prevented tubule formation by 95% when added on day 2 and significantly reduced tubule formation by 59% when added on day 7 compared to control co-cultures. Incubating co-cultures with IL-6 significantly promoted tubule formation by 46% when added on day 2 compared to control co-cultures. Whilst tubule formation was further increased by 57% when added on day 7 compared to control co-cultures, this was not statistically significant.

These results indicate TNFα and IL-6 altered several in vitro cell activities that are relevant to angiogenesis as expected, including cell viability and tubule formation.
Fig. (2). (A) Tubule formation and growth assessed with MCAM and Collagen type IV staining of a typical co-culture on day 14. (B) Tubule formation over time (3 – 14 days) assessed by MCAM staining. (C) Tubule formation and growth assessed with MCAM staining at day 14 in co-cultures grown in EGM-2, EGM-2 + 50 ng/mL VEGF, EGM-2 + 50 ng/mL VEGF + 50 ng/mL anti-VEGF and EGM-2 + 50 ng/mL anti-VEGF added on day 0. Medium was changed every 4 days. Each image is representative of 3 independent experiments; within an experiment, each treatment was carried out in duplicate and observed in three randomly chosen fields. Magnification 40x.
Fig. (3). (A) Tubule formation and growth assessed with MCAM staining at day 14 in co-cultures grown in EGM-2 and EGM-2 (added on day 2), and EGM-2+TNFα (10 ng/mL) or EGM-2+IL-6 (10 ng/mL) added on day 2 or 7 after co-culture establishment, respectively. Medium was changed every 4 days. Images presented are representative of treatments from 3 independent experiments; within an experiment, each treatment was carried out in duplicate and observed in three randomly chosen fields. Magnification 40x. (B) Quantification of total tubule length determined using AngioSys software. Cytokines added on day 2 (black bars) and day 7 (white bars). Results are presented as a percentage of EGM-2 as mean ± SEM of 3 independent experiments; within each experiment, each treatment was carried out in duplicate; *P<0.05, **P<0.01, ***P<0.001.

Measurement of VEGF, E-selectin and PGE2 Production from HUVEC/NHDF Co-cultures

The effect of TNFα or IL-6 in vitro was evaluated in relation to the production of the well-characterised angiogenic factor and signalling factor for malignant progression, VEGF, of the adhesion molecule E-selectin and of the protumourigenic prostanoid PGE2, which are markers of inflammation (Fig. 4). VEGF, E-selectin and PGE2 levels were measured by ELISA, in the medium collected from HUVEC/NHDF co-cultures cultured over 14 days, in EGM-2 medium, EGM-2, EGM-2+TNFα or EGM-2+IL-6 (Fig. 4). Conditioned medium was collected after 2, 7 and 14 days for EGM-2 medium and EGM-2 incubated co-cultures and for EGM-2+TNFα or EGM-2+IL-6 incubated co-cultures on days 7 and 14. Results are presented as percentage change from the control (i.e., EGM-2) on day 14.
Firstly, measurement of VEGF levels revealed no significant changes in medium collected on day 14, from co-cultures incubated with EGM-2 medium or EGM-2Ө+IL-6 compared to control (Fig. 4A). This result suggests that VEGF is utilised for tubule development in this co-culture system and does not accumulate in the conditioned medium. Medium collected from EGM-2Ө+TNFα incubated co-cultures contained higher VEGF levels (50% and 72% increase when TNFα was added after 2 and 7 days, respectively) than in the control. A statistically significant increase in VEGF was observed when TNFα was added on day 7 (and collected on day 14) (Fig. 4A). The increased levels of VEGF in medium collected from TNFα treated co-cultures mirror the decrease in total tubule length (Fig. 3B). Secondly, results obtained from E-selectin measurement show no significant changes in E-selectin expression, except for a significant increase (508%) in E-selectin expression with TNFα on day 7 (added on day 2) compared to control (Fig. 4B). Finally, measurement of PGE₂ shows that there were no significant effects on PGE₂ secretion, irrespective of treatment, when compared to control, except for when co-cultures were incubated with EGM-2 medium (20% decrease) or EGM-2Ө+IL-6 (24% decrease) added on day 2 (and collected on day 14) (Fig. 4C).

Fig. (4). Changes in (A) VEGF expression (%) detected by a DuoSet human ELISA kit, (B) E-selectin expression (%) detected by a DuoSet human ELISA kit, and (C) PGE₂ expression (%) detected by a Parameter human ELISA kit in the medium of HUVEC/NHDF co-cultures cultured, over 14 days, in EGM-2Ө, EGM-2 (positive control for tubule formation), EGM-2Ө+TNFα (10 ng/mL) or EGM-2Ө+IL-6 (10 ng/mL). Results are presented as a percentage of EGM-2Ө as mean ± SEM of 3 independent experiments; within each experiment, each treatment was carried out in duplicate; *P<0.05, **P<0.01. Note the changes to the % expression scale (i.e., y axis).
Effect of TNFα or IL-6 on MMP Enzyme Activity

To analyse if modulation of angiogenesis by TNFα or IL-6 was associated to changes in the enzyme activity of proteases involved in matrix remodelling, MMP-2 and MMP-9 enzyme activity were measured by gel zymography. Medium from HUVEC and NHDF grown individually or in combination, as HUVEC/NHDF co-cultures, was assayed as described in Materials and Methods. The activity of MMP enzymes was visualised as areas of gelatinolytic enzyme activity which appear clear against the dark background of Coomassie Blue stained gels. Gels were analysed using Image J software and the molecular weight of each MMP band determined: 92 kDa for MMP-9, 72 kDa for pro-MMP-2 (inactive pro-enzyme) and 62 kDa for active-MMP-2 (cleaved, activated enzyme). No bands were detected in control gels incubated in the presence of EDTA (data not shown).

The activity of MMP enzymes was initially determined in the medium of HUVEC and NHDF individually (Fig. 5). Cell culture medium was collected on days 2, 7, 10 and 14 after culture establishment and results show only pro-MMP-2 (inactive form) (Fig. 5A). Pro-MMP-2 activity was quantified and a statistically significant increase in pro-MMP-2 activity was observed in a time-dependent manner in both NHDF and HUVEC. Activity increased by 5- and 8-fold at day 7 and 10 of co-culture, respectively, in NHDF compared to activity at day 2. No further statistically different increase was observed at day 14. Similarly, activity increased by 8- and 11-fold respectively, in HUVEC compared to activity on day 2, with no further increase observed at day 14.

MMP-9 and active-MMP-2 were not detected in NHDF and HUVEC when cultured individually (Fig. 5), however, in co-culture (medium collected at final end point - day 14), these MMP enzymes could be detected using gel zymography (Fig. 6A). The results show pro-MMP-2 activity was higher than active-MMP-2 activity when tubules were formed in control (i.e., EGM-2Ω) incubated co-cultures and in co-cultures grown with EGM-2 medium (statistically significant difference, \( P<0.05 \)) or EGM-2Ω+IL-6 (Fig. 6B and C), with the exception of co-cultures incubated with EGM-2Ω+TNFα on day 2 and 7 when tubules were not formed (statistically significant difference \( P<0.05 \) when TNFα added on day 7, but not when added on day 2) (Fig. 6B and C). Similar levels of pro-MMP-2 were observed irrespective of treatment. Active-MMP-2 activity increased in EGM-2Ω+TNFα treated co-cultures (no tubules) compared to control co-cultures but this was not statistically significant. This trend was similar for treatments added on day 2 or day 7. No MMP-9 activity was found in any of these samples. However, in TNFα treated co-cultures, significantly higher levels of MMP-2 (i.e., active-MMP-2 when TNFα was added on day 7) and MMP-9 activity (when TNFα was added on day 2 and day 7) were seen compared to control (Fig. 6B and C). Interestingly, MMP-9 activity correlated with absence of tubules, whilst MMP-2 activity corresponds to the presence of tubules (Fig. 3A and B). Activation of MMP-2 (i.e., ratio between active over pro-form) was differentely regulated in co-cultures grown in EGM-2 medium or EGM-2Ω compared to co-cultures treated with IL-6 or TNFα. A ratio <1, observed in cells grown in EGM-2 medium, EGM-2Ω and EGM-2Ω+IL-6, correlated with tubule formation whereas a ratio >1 observed in cells grown in EGM-2Ω+TNFα resulted in little or no tubule formation. This result suggests that, according to the treatments investigated in this study, a correlation exists between tubule formation and MMP enzyme activity: tubules may partly be produced by modulating the activity of different MMP enzymes. Because it is possible MMP enzyme activity changed in function of total protein secretion which in turn could alter tubule formation, the concentration of total protein secreted into the medium (from HUVEC and NHDF cultured individually or in co-culture) was determined using the Bradford protein assay. There were, however, no differences in the concentration of total protein secreted between any of the test conditions and time points (data not shown).

![Fig. (5).](image)

(A) Pro-MMP-2 activity in NHDF and HUVEC cultured over 14 days. MMP enzymes released from cells into the medium on days 2, 7, 10 and 14 was collected and analysed by gel zymography. Images presented are representative of 3 independent experiments. (B) Quantification of pro-MMP-2 activity using Image J software. Results are presented as mean ± SEM of 3 independent experiments; *\( P<0.05 \), **\( P<0.01 \), ***\( P<0.001 \).
DISCUSSION

In this study, the effects of two inflammatory cytokines, TNFα and IL-6 were investigated. Experiments included assessing cell viability, tubule formation, secretion of VEGF, E-selectin and PGE₂, and MMP enzyme activity using a more versatile in vitro HUVEC/NHDF co-culture system compared to the one developed by Bishop et al. [15]. This system has been established appositely and characterised (Fig. 2) to allow in depth studies of the role of specific molecules in modulating angiogenesis in addition to the heterogeneous cellular environment formed.

This study showed that both HUVEC and NHDF were more responsive to TNFα than IL-6; indicating that TNFα induced greater changes to cell viability than IL-6. Additionally, TNFα significantly decreased the formation of tubules. In contrast, and similar to the results observed in co-cultures grown in EGM-2 medium, IL-6 significantly increased tubule formation. TNFα completely prevented formation of tubules when added on day 2 and stopped any further development of tubule formation once the process had already started as evident when added on day 7. IL-6, on the contrary, promoted the formation of tubules when added on day 2 and increased tubule formation once the process had already started as evident when added on day 7. These observations on tubule formation further indicate that angiogenesis is modulated by specific inflammatory markers. Additionally, this study has highlighted the importance of considering the time after tubule initiation when observing the generation and growth of endothelial tubules. This is the first time that a time course after initial tubule formation has been investigated and reported in the literature. Limited reports are available on the effect of TNFα or IL-6 alone in an in vitro co-culture cell system, except for a study conducted by Hashizume and colleagues [26]. Their study used fibroblast-like synovial cells from rheumatoid arthritis patients and HUVEC co-cultures to examine the effect of TNFα in tubule formation over 21 days; neither TNFα nor IL-6 induced tubule formation. Hashizume and colleagues [26] measured the final outcome (i.e., tubule formation after 21 days co-culture) and did not differentiate between promoting/preventing or increasing/reducing angiogenesis which was examined in this study. Furthermore, secretion of key angiogenic/tumourigenic factors and re-modelling of ECM via MMP activity has not been fully investigated previously in relation to TNFα or IL-6. These factors have been investigated in more detail in this work in order to improve the understanding of the role of cytokines in modulating angiogenesis.
It is well known that VEGF is one of the most important factors for accelerating angiogenesis [17]. In order to determine the relationship between tubule formation and release of VEGF, the concentration of VEGF secreted into conditioned medium was investigated using ELISA. Results revealed that co-culture treatment with TNFα induced an increase in secretion or accumulation of VEGF in the medium compared to co-cultures grown in EGM-2O and the increase in concentration paralleled the lack of tubules formed. These observations support previous studies which emphasise the key role and requirement of VEGF in new tubule formation [27].

During inflammation, EC are activated by inflammatory cytokines, such as TNFα, interleukin-1 (IL-1) and interferon γ (IFNγ), which induce up-regulation of adhesion molecules expression including E-selectin [28]. E-selectin (CD62E) is an EC-specific adhesion molecule involved in initial vessel wall binding [29]. Although expression of E-selectin has been previously described in single-cell conditions [30], insight into the regulation of E-selectin expression and endothelial functioning following incubation with inflammatory cytokines remains, to the best of our knowledge, to be determined in an in vitro EC/fibroblast co-culture system.

Results in this study revealed no change in E-selectin expression, except for co-cultures grown in EGM-2O+TNFα. This may suggest that the time points selected for medium analysis (collected on days 2, 7 or 14 after initial establishment of the HUVEC/NHDF co-culture system) were not ideal to observe any changes in E-selectin expression with EGM-2, EGM-2O or EGM-2O+IL-6; especially since this is an early event in angiogenesis. Previous studies have shown time-dependent up-regulation of E-selectin expression, observed by immunofluorescence, in HUVEC activated with TNFα (4 ng/mL) [28]. Griffioen and colleagues [28] also observed up-regulation of E-selectin expression by IL-1α and IFNγ. Similarly, Mason and colleagues [31] observed E-selectin up-regulation, via surface and mRNA expression, in HUVEC stimulated with TNFα (10 ng/mL). The results presented in this study showed, for the first time, that cells grown in a co-culture system (HUVEC/NHDF) also increased E-selectin expression when stimulated with TNFα. Also, as E-selectin mRNA expression is barely detectable in unstimulated HUVEC [31], it is unsurprising that E-selectin expression was only observed in co-cultures treated with EGM-2O+TNFα because TNFα itself will further induce inflammation. Furthermore, it has been shown that angiogenic growth factors (e.g., bFGF and VEGF) suppress inflammatory cytokine-induced up-regulation of E-selectin, as well as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) [28, 32]. In the experimental set-up used in this study, the EC/fibroblast co-culture system is grown in the recommended endothelial growth medium (EGM-2) which contains a mixture of growth factors, including bFGF and VEGF, which may influence the observed responses.

The protumourigogenic prostanooid PGE2 is involved in promotion of angiogenesis [33, 34] and its production is known to be activated by inflammatory cytokines (IL-1β, IL-6 or TNFα) [35]. Similar to E-selectin, PGE2 secretion has been previously described in single-cell conditions in relation to angiogenesis [36], but, to our knowledge, its production remains to be determined in an in vitro EC/fibroblast co-culture system. Based on this information, our focus was driven by the assumption that the effect of TNFα or IL-6 on tubule formation could be mediated by PGE2 production. Results from this study showed that the presence of tubules (incubation with EGM-2 medium and EGM-2O+IL-6) decreased PGE2 secretion, whilst the absence of tubules (incubation with EGM-2O+TNFα) did not change PGE2 production compared to the control. Therefore, secretion of PGE2 was not evident in the medium collected on day 14 from the co-culture system. PGE2 is (i) rapidly released in response to inflammation [37], (ii) responsible for stimulation of EC migration and proliferation [38, 39] and, therefore, (iii) an important early event in angiogenesis, which confers that the time point selected for analysis of PGE2 secretion (collected on day 14 after initial establishment of HUVEC/NHDF co-culture system) was limiting to observe any changes in production. However, the findings presented do give new insight into the role of PGE2 or lack thereof in tubule formation.

An initial step in the angiogenic process is degradation of the ECM [20, 21]. Following matrix breakdown, EC migrate and proliferate to form new vessels. Therefore, proteolytic enzyme activity, which degrades all components of the ECM, is essential for the initial process of angiogenesis and is performed by MMP enzymes [20, 21]. At present, regulation of MMP activity and the balance between MMP enzymes and their major inhibitors, Tissue Inhibitor of Metalloproteinases (TIMP) play a key role in EC migration and proliferation during angiogenesis [22, 40]. Given the important role of MMP enzymes in angiogenesis, the enzyme activity of MMP-2 and MMP-9 was measured in the media of HUVEC and NHDF individually and at the end point of co-culture incubation (day 14) in order to correlate enzyme activity to tubule formation using the widely accepted method of gel zymography. Untreated HUVEC and NHDF did not produce detectable MMP-9. The pro-form of MMP-2 (72 kDa) was, however, visible in HUVEC and NHDF in this study. This data are in agreement with previous gel zymography studies reported in the literature: Jiang and colleagues [41] and Oak and colleagues [27] found only pro-MMP-2 expression in medium collected from cultured HUVEC, whilst Mauro and colleagues [42] detected the expression of pro-MMP-2 and MMP-9 in conditioned medium from cultured HUVEC. However, this was in contrast to what was observed in here, but the different medium used by Mauro et al. [42] could be responsible. Additionally, literature searches have shown little or no information is available for the enzyme activity of MMP-2 or MMP-9 in NHDF.

This study provides the first evidence that inflammatory markers can alter tubule formation in relation to the production and activity of MMP enzymes observed, at a final end point, in a heterogeneous cellular environment. Secretion of MMP-9 and activation of MMP-2 correlated with an absence of tubules, whilst the opposite was observed with the presence of tubules. In detail, treatment with TNFα resulted in MMP-9 production and activation of MMP-2 (62 kDa). There is evidence to suggest that TNFα may be crucial in MMP production, in fact, it is known
that TNFα (10 ng/mL) stimulates MMP-9 expression via activation of ERK1/2 in HK-2 proximal tubular cells [43] or via activation of NFκB in monocytes [44]. It remains to be seen whether these mechanisms are responsible for MMP-9 production in this co-culture system and the investigation of the mechanisms by which MMP-9 expression is induced in the absence of tubule formation is currently on-going.

Additionally, the role of MMP enzymes in obesity associated inflammation still remains unclear, but a recent study by Miksztowicz and colleagues [45] found increased plasma activity of pro-MMP-2 in overweight/obese women (BMI 25-38.5 kg/m², n=26) compared to normal weight women (BMI 18-24.9 kg/m², n=13). Although these authors did not determine the origin of the measured pro-MMP-2, it is typically produced in most human tissue cell types, including adipose tissue. Interestingly, elevated levels of MMP-2 are associated with invasive behaviour [23] and findings reported here showed that pro-MMP-2 activity was higher than active-MMP-2 activity in co-cultures in the presence of tubules. Therefore, MMP-2 could be a key factor in angiogenesis and play an important role in tubule formation and cell-cell interactions.

The versatile co-culture model which utilised primary HUVEC co-cultured with primary NHDF was used to study the role of two cytokines, TNFα or IL-6, typically associated with obese status in modulating new blood vessel formation in vitro. EC become organised amongst the fibroblasts as cored structures which proliferate, thicken and lengthen through the cell matrix to form an intricate network of tubule structures over 14 days which are well established features [15]. Although studies have reported similar conclusions for TNFα [46-48] and IL-6 [49-51] in single cells to the one presented, the further development of the co-culture model by Bishop and colleagues [15] allowed a more versatile and flexible approach to investigate angiogenesis, and its progression, relative to single cell studies. This study has further characterised, from a technical point of view, this in vitro co-culture system especially in relation to manipulation of medium components and time of addition (after 2 days vs 7 days) of key inflammatory markers. Finally, this study has enabled us to reach a stage where the system can be manipulated according to specific requirements and allows for a more detailed understanding of the role of inflammatory cytokines in the development of new blood vessels in direct relation to MMP activity and secretion of key angiogenic markers. Interestingly, the concentrations of cytokines used in the study have been shown by Bermano’s group to play a role in the link between obesity and breast cancer [52] and this work will be taken forward in the context of obesity, breast cancer and angiogenesis ex vivo and in vivo.

CONCLUSIONS

In summary, this observational study showed treatment-specific differences in the regulation of angiogenesis and MMP activity. These findings show that it is critical to further improve understanding of how inflammatory cytokines can specifically contribute to the development of vascular complications in chronic inflammatory conditions such as the ones associated to obesity. In light of this, investigations in the effect of plasma from obese versus non-obese individuals using this versatile EC/fibroblast co-culture system are currently being explored.

LIST OF ABBREVIATIONS

| EC          | Endothelial cells Extracellular matrix |
| ECM         | Human umbilical vein endothelial cells |
| HUVEC       | Human umbilical vein endothelial cells |
| IL-6        | Interleukin-6 |
| MMP         | Matrix metalloproteinases |
| NHDF        | Normal human dermal fibroblasts |
| PGE2        | Prostaglandin E2 |
| TNFα        | Tumour necrosis factor-α |
| VEGF        | Vascular endothelial growth factor |

Coding for the different types of medium used: Endothelial basal medium (EBM-2) supplemented with SingleQuots (EGM-2 medium); EGM-2 medium minus the SingleQuot of VEGF (EGM-2O); EGM-2 medium minus the SingleQuot of VEGF supplemented with TNFα (10 ng/mL) (EGM-2O+TNFα); EGM-2 medium minus the SingleQuot of VEGF supplemented with IL-6 (10 ng/mL) (EGM-2O+IL-6).

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

Authors would like to thank TENOVUS Scotland and the Institute for Health and Wellbeing Research, Robert Gordon University for financial support.
ACKNOWLEDGEMENTS

GB conducted the HUVEC/NHDF co-culture experiments, collected and analysed data, wrote & edited the manuscript. MG and GB designed the study, wrote & edited the manuscript. All authors read and approved the submitted version of the manuscript.

REFERENCES

[1] Olszanecka-Gliniawicz Z, Zahorska-Markiewicz B, Janowska J, Zurakowski A. Serum concentration of nitric oxide, tumor necrosis factor (TNF)-α and TNF soluble receptors in women with over- weight and obesity. Metabolism 2004; 53: 1268-73.
[2] Hansen D, Dendale P, Beelen M, et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol 2010; 109: 379-404.
[3] Vistropolsky Y, Trofinov M, Malkin I, Kobyliansky E, Livshits G. Genetic and environmental determinants of hepatocyte growth factor levels in rats and their association with obesity and blood pressure. Ann Hum Biol 2008; 55: 93-103.
[4] Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr-Relat Cancer 2007; 14: 189-206.
[5] Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link? Biochem Pharmacol 2006; 72: 1605-21.
[6] Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol 2010; 316: 104-8.
[7] Pandya NM, Dhalla NS, Santani DD. Angiogenesis – a new target for future therapy. Vase Pharmacol 2006; 44: 265-74.
[8] Bastelica D, Mavri A, Verdierl M, Berthet B, Juhan-Vague I, Alessi MC. Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNF al-pha receptors to PAI-I levels. Thromb Haemost 2002; 88: 481-7.
[9] Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dando P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 1564-71.
[10] Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue angiogenesis and development of adiposity and breast cancer. Biochim Biophys Acta 2013 Doi: 10.1016/j.bbalip.2013.02.010
[11] Alexandrakis MG, Tsirakis G. Circulating levels of soluble angiogenic factors in multiple myeloma: correlation with parameters of disease activity and prognosis. Curr Angiogen 2013; 2: 76-95.
[12] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996; 86: 353-64.
[13] Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2001; 473: 298-307.
[14] Lijnen HR. Angiogenesis and Obesity. Cardiovasc Res 2008; 78: 286-93.
[15] Bishop ET, Bell GT, Bloor S, Broom H. An in vitro model of angiogenesis: basic features. Angiogenesis 1999; 3: 335-44.
[16] Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003; 9: 1144-55.
[17] Christiaens V, Lijnen HR. Angiogenesis and development of adipose tissue. Mol Cell Endocrinol 2010; 318: 2-9.
[18] Barbera-Guillen E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular Endothelial growth factor secretion by tumour-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002; 62: 7042-9.
[19] Lee CC, Liu KJ, Huang TS. Tumor-associated macrophage: Its role in tumor angiogenesis. J Cancer Mol 2006; 2: 135-40.
[20] Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995; 105: 170-6.
[21] Raza SL, Cornelius LA. Matrix metalloproteinases: Pro- and anti-angiogenic activities. J Invest Dermatol 2000; 5: 47-54.
[22] Connelly L, Robinson-Benion C, Chont M, et al. A transgenic model reveals important roles for the NF-κB alternative pathway (p100/p52) in mammary development and links to tumourigenesis. J Biol Chem 2007; 282: 10028-35.
[23] Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Bio 2002; 37: 375-536.
[24] Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human ‘angiogenesis’ assays with capillaries formed in vivo. Angiogenesis 2001; 4: 113-21.
[25] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
[26] Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/IL-6R trans-signalling, but not TNF-α induced angiogenesis in an HU-VEC and synovial cell co-culture system. Rheumatol Int 2009; 29: 1449-54.
[27] Oak J-H, Nakagawa K, Okawa S, Miyazawa T. Amadori- glycatedphosphatidylethanolamine induces angiogenic differentiation in cultured human umbilical vein endothelial cells. FEBS Lett 2003; 555: 419-23.
[28] Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumour angiogenesis is accompanied by a decreased expression of re- sensitive of tumour-associated endothelium. Blood 1996; 88: 667-73.
[29] Rahman A, Kefer J, Bando M, Niles WD, Malkl AB, E-selectin expression in human endothelial cells by TNF-α-induced oxidant generation and NF-κB activation. Am J Phys 1998; 275: L533-44.
[30] Unger RE, Krampe-Konvalinka V, Peters K, Kirkpatrick CJ. In vitro expression of the endothelial phenotype: Comparative study of primary isolated cells and cell lines, including the novel cell line HPMEC-ST1.6R. Microvasc Res 2002; 64: 384-97.
[31] Mason JC, Jarwood H, Sugars K, Haskard DO. Human umbilical vein and dermal microvascular endothelial cells show heterogeneity in response to PKC activation. Am J Physiol 1997; 273: C1233-40.
[32] Zhang H, Isselkutz AC. Down-modulation of monocyte transendo- thelial migration and endothelial adhesin molecule expression by fibroblast growth factor. Am J Pathol 2002; 160: 2219-30.
[33] Form DM, Auerbach R. PGE, and angiogenesis. Proc Soc Exp Biol Med 1983; 172: 214-8.
[34] Díaz-Flores L, Gutierrez R, Valladares F, Varela H, Perez M. In- tense vascular sprouting from rat femoral vein induced by prostaglandins E, and E2. Anat Rec 1994; 238: 68-76.
[35] Bishop-Bailey D, Mitchell JA, Warner TD. COX-2 in cardiovascular disease. Arterioscler Thromb Vase Biol 2006; 26: 956-8.
[36] Brecht K, Weigert A, Hu J, et al. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J 2011; 25: 1-10.
[37] Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 2001; 276: 36993-8.

[38] Rao R, Redha R, Macias-Perez I, et al. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 2007; 282: 16959-68.

[39] Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 2008; 283: 2139-46.

[40] Stamenkovic I. Extracellular matrix modelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-64.

[41] Jiang C, Ganther H, Lu J. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: Implications for angiogenic switch regulation. Mol Carcinogen 2000; 29: 236-50.

[42] Mauro A, Buscemi M, Gerbino A. Immunohistochemical and transcriptional expression of matrix metalloproteinases in full-term human umbilical cord and human umbilical vein endothelial cells. J Mol Histol 2010; 41: 367-77.

[43] Nee LE, McMorrow T, Campbell E, Slattery C, Ryan MP. TNFα and IL-1β-mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. Kidney Int 2004; 66: 1376-86.

[44] Nguyen J, Goqusev J, Knapnougel P, Bauvois B. Protein tyrosine kinase and p38 MAP kinase pathways are involved in stimulation of matrix metalloproteinase-9 by TNF-alpha in human monocytes. Immunol Lett 2006; 106: 34-41.

[45] Miksztowicz V, Siseles, N, Fernandez Machulsky N, Schreier L, Berg G. Increase in MMP-2 activity in overweight and obese women is associated with menopausal status. Climacteric 2012; 15: 602-6.

[46] Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-α. Nature 1987; 329: 630-2.

[47] Koolwijk P, van Erck MGM, de Vree WJA, et al. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix role of urokinase activity. J Cell Biol 1996; 132: 1177-88.

[48] Siekerink MI, Klaassen I, Vogels IMC, Griffioen AW, van Noor-den CJF, Schlingemann RO. CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis 2012; 15: 151-63.

[49] Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990; 87: 3092-6.

[50] Huang SP, Wu MS, Shun CT, et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biol Med Sci 2004; 11: 517-27.

[51] Hsu SC, Chu CY, Chiu HC, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 2004; 123: 1169-75.

[52] Weichhaus M, Broom I, Bermanno G. The molecular contribution of TNF-α in the link between obesity and breast cancer. Oncol Rep 11; 25: 477-83.